[ Ссылка ]
Overview:
Part 1: As the world’s population ages, rates of neurodegenerative disease are increasing. Research into familial forms of these diseases is providing insight into cellular mechanisms.
Part 2: Petsko’s lab has shown that cleavage of α-synuclein by caspase-1 causes α-synuclein to form aggregates. This may be a critical step in the development of Parkinson’s disease.
Part 3: Studies in yeast and neuronal models have allowed Petsko’s lab to identify genes that suppress protein aggregation found in ALS.
Talk Description:
Dr. Petsko begins his lecture by presenting the challenges associated with a growing elderly population and a shrinking work force. As the population ages, we face an epidemic of debilitating neurodegenerative disease that will take a great financial and emotional toll on family, caregivers and society. The brains of patients with Alzheimer’s, Parkinson’s, and ALS/Lou Gehrig’s diseases are characterized by the presence of protein aggregates due to protein misfolding. While most neurodegenerative disease arises sporadically, about 10% has a direct genetic cause. Petsko explains that by studying the familiar forms, scientists have gained great insight into the cellular and molecular processes underlying these devastating diseases.
In Part 2, Petsko focuses on Parkinson’s disease, the second most common neurodegenerative disease after Alzheimer’s. Petsko and his colleagues studied patients with a genetic predisposition to Parkinson’s disease and found a mutation in the α-synuclein gene that caused the protein to misfold and aggregate. In sporadically occurring cases of Parkinson’s, they discovered that α-synuclein was cleaved and the resulting protein fragment formed aggregates. Switching to yeast as a model system and then to human cells, Petsko’s lab identified caspase-1 as the protease responsible for cleaving α-synuclein. Interestingly, caspase-1 is activated during inflammation, providing a possible explanation for how head injury and brain infection may contribute to Parkinson’s. The development of caspase-1 inhibitors that can penetrate the brain would present hope for an effective treatment for Parkinson’s disease.
Petsko and others also studied patients with familial amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease and he describes this work in Part 3. They knew that many of the genes mutated in ALS encode RNA-binding proteins and these proteins formed aggregates in neurons from ALS patients. Expression of two of these proteins, FUS and TDP43, in yeast resulted in the same phenotype. A screen for yeast genes that would suppress FUS/TDP43 toxicity identified five genes and all encoded RNA binding proteins. Excitingly, several of the human homologs of these genes also were shown to block FUS/TDP43 toxicity in human neuron and neonatal rat models. These encouraging results generate hope that targeted gene therapy may provide a future treatment for this terrible neurodegenerative disease.
Speaker Biography:
Gregory Petsko is Arthur J. Mahon Professor of Neuroscience in the Brain and Mind Research Institute at Weill Cornell Medical College. His lab studies protein structure and function with a particular focus on understanding and developing treatments or preventative therapies for age-related neurodegenerative diseases.
Petsko received his B.A. from Princeton University. He was awarded a Rhodes Scholarship and completed his D.Phil. from Oxford University where he studied in Sir David Chilton Phillips’ lab.
Petsko is an elected member of the National Academy of Sciences and the Academy of Medicine and has received numerous other honors and awards.
Learn more about Dr. Petsko: [ Ссылка ]
